| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$129 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 10:54AM |
$0.245 |
$0.330 |
risen by
34.69%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$129 |
Appendix 4E and 2024 Annual Report
|
30 Aug 2024 10:53AM |
$0.245 |
$0.330 |
risen by
34.69%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing activities decreased by 24.02% compared to the previous period.
- Loss from continuing activities after tax increased by 12.99% to $58,653,188.
- No dividends were declared for the period.
- Net tangible asset backing per ordinary share decreased from 18.00 cents to 5.95 cents.
- Basic and diluted earnings per share were both (20.00) cents.
- The report includes detailed remuneration information for key management personnel.
- Remuneration for the Chief Medical Officer was formalized in a service agreement starting 1 September 2019.
- For the financial year 2024, the Board determined not to award Short-Term Incentives (STIs).
- Paradigm Biopharmaceuticals Limited is a late-stage clinical development company focused on improving patients’ health and quality of life.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$12 |
Securities Trading Policy
|
30 Aug 2024 10:52AM |
$0.009 |
$0.006 |
fallen by
33.33%
|
|
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$12 |
Preliminary Final Report
|
30 Aug 2024 10:51AM |
$0.009 |
$0.006 |
fallen by
33.33%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Memphasys Limited focuses on developing and commercializing reproductive biotechnology products.
- Main product: FelixTM System, an automated device for sperm separation in IVF procedures.
- FelixTM System is commercially sold in Japan through an exclusive agreement with Vitrolife Japan KK.
- Positive clinical trials in Japan show FelixTM System improves IVF success rates and efficiency.
- Additional markets: Canada and New Zealand have exclusive distribution agreements for the FelixTM System.
- Developing RoXstaTM, an oxidative stress measurement system, with potential applications in human and animal health.
- Financial performance for FY2024 includes a net loss of AUD 4,442,021, attributed to increased R&D costs and termination payments.
- Key strategic partnerships and industry engagements have been crucial for product commercialization.
- Memphasys is undertaking a larger clinical trial in Australia for the FelixTM System, with expected completion by the end of the calendar year.
- Exploring early access markets with fewer regulatory hurdles for faster commercial entry.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harris Technology Group Limited (HT8) ORDINARY FULLY PAID |
Consumer Discretionary |
$3 |
Corporate Governance Statement
|
30 Aug 2024 10:49AM |
$0.011 |
$0.010 |
fallen by
9.09%
|
|
| Harris Technology Group Limited (HT8) ORDINARY FULLY PAID |
Consumer Discretionary |
$3 |
Appendix 4G
|
30 Aug 2024 10:47AM |
$0.011 |
$0.010 |
fallen by
9.09%
|
|
| Mighty Kingdom Limited (MKL) ORDINARY FULLY PAID |
Communication Services |
$4 |
Completion of Consolidation of Capital
|
30 Aug 2024 10:44AM |
$0.055 |
$0.008 |
fallen by
85.45%
|
|
| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$7,446 |
NZX Performance Rights Update
|
30 Aug 2024 10:40AM |
$32.320 |
$36.640 |
risen by
13.37%
|
|
| Aims Property Securities Fund (APW) ORDINARY UNITS FULLY PAID |
Real Estate |
$118 |
TOV: APW - Panel Receives Review Application
|
30 Aug 2024 10:39AM |
$1.605 |
$2.640 |
risen by
64.49%
|
|
| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$7,446 |
NZX Capital Change Notice
|
30 Aug 2024 10:39AM |
$32.320 |
$36.640 |
risen by
13.37%
|
|
| Harris Technology Group Limited (HT8) ORDINARY FULLY PAID |
Consumer Discretionary |
$3 |
Preliminary Final Report
|
30 Aug 2024 10:38AM |
$0.011 |
$0.010 |
fallen by
9.09%
|
|
HT8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the year ended 30 June 2024 was $16,708,641, a decrease of 31% from the previous corresponding period.
- Net loss from continuing operations for the year ended 30 June 2024 was $1,406,794, an improvement of 57% from the previous corresponding period.
- The company does not propose to pay a dividend.
- Sales revenue declined but was in line with the shift to a higher margin mix of products.
- Harris Technology entered the refurbished IT products category, showing good success and contributing towards increasing average margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Serko Limited (SKO) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$355 |
Capital Change Notice
|
30 Aug 2024 10:37AM |
$2.900 |
$2.880 |
fallen by
0.69%
|
|
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,277 |
Date of 2024 AGM and Closing Date for Director Nominations
|
30 Aug 2024 10:34AM |
$11.620 |
$19.120 |
risen by
64.54%
|
|
| Sayona Mining Limited (SYA) ORDINARY FULLY PAID |
Materials |
$185 |
FY2024 Results Presentation
|
30 Aug 2024 10:34AM |
$0.027 |
$0.016 |
fallen by
39.62%
|
|
SYA - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 full year results presentation held on 30 August 2024
- Significant increase in ore mined and spodumene concentrate production
- Revenue of A$201 million and underlying EBITDA loss of A$54 million
- Cash balance of A$91 million at the end of FY24
- Exploration activities delivered substantial increases in mineral resource estimates
- Loss from operations driven by A$65 million of non-cash extraordinary items and depreciation
- Formation of Audit and Risk Committee and Nomination and Remuneration Committee
- Appointment of Philip Lucas as NED and Lucas Dow as NED, MD, and CEO
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helix Resources Limited (HLX) ORDINARY FULLY PAID |
Materials |
$8 |
Change in substantial holding
|
30 Aug 2024 10:33AM |
$0.005 |
$0.003 |
fallen by
44.44%
|
|
| Sayona Mining Limited (SYA) ORDINARY FULLY PAID |
Materials |
$185 |
FY2024 Results Announcement
|
30 Aug 2024 10:33AM |
$0.027 |
$0.016 |
fallen by
39.62%
|
|
SYA - Price-sensitive ASX Announcement
Full Release
Key Points
- North American Lithium (NAL) nearing steady-state operations by end of FY24
- Total concentrate production of 155,822 dmt for FY24
- Record monthly production of 19,314 tonnes in May 2024
- Spodumene concentrate shipments totalled 157,937 dmt
- Lithium recoveries improved to 68% for the June quarter
- Major capital projects completed at NAL including Crushed Ore Dome and Tailings Storage Facility
- Maiden full year revenues of $201 million
- Underlying EBITDA loss of $54 million
- Group loss after income tax of $119 million
- Investment in capital and exploration projects totalling $128 million
- Cash balance at end of year: $91 million
- Guidance for FY25 includes 190,000 – 210,000 dmt concentrate production
- Sayona’s strategy includes optimizing operations, expansion through drilling programs, and strategic partnerships
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helix Resources Limited (HLX) ORDINARY FULLY PAID |
Materials |
$8 |
Becoming a substantial holder
|
30 Aug 2024 10:33AM |
$0.005 |
$0.003 |
fallen by
44.44%
|
|
| Helix Resources Limited (HLX) ORDINARY FULLY PAID |
Materials |
$8 |
Intention to Make Takeover Bid
|
30 Aug 2024 10:33AM |
$0.005 |
$0.003 |
fallen by
44.44%
|
|
HLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement of a proportional all-cash off-market takeover offer by Acta Investment Group Pty Ltd.
- Offer to acquire 25% of all ordinary shares of Helix that Acta and its associates do not currently hold or control.
- Acta and its associate Nuevo Royalty Limited currently hold a 9.42% stake in Helix.
- Offer price set at $0.005 per share, representing a 39% premium to Helix's 30-day VWAP.
- Bidder's Statement to be provided within 2 months, detailing how shareholders can accept the offer.
- Conditions and prescribed occurrences laid out in Annexure A.
- Helix not to proceed with any alternative proposals or offers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sayona Mining Limited (SYA) ORDINARY FULLY PAID |
Materials |
$185 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 10:33AM |
$0.027 |
$0.016 |
fallen by
39.62%
|
|
| Vectus Biosystems Limited (VBS) ORDINARY FULLY PAID |
Health Care |
$3 |
Agreement with C14 Consulting Group
|
30 Aug 2024 10:32AM |
$0.087 |
$0.065 |
fallen by
25.29%
|
|
VBS - Price-sensitive ASX Announcement
Full Release
Key Points
- Vectus Biosystems Limited (VBS) has appointed C14 Consulting Group, LLC in an exclusive role.
- C14 will lead and manage potential licensing, joint ventures, or both for Vectus’ portfolio of patented small therapeutic molecules.
- VB0004 along with A32 and A79 target reversal of disease in the heart, lung, kidney, and liver.
- VB0004 has successfully undergone Phase Ia and Phase Ib human trials with no adverse events.
- C14 Consulting Group, led by CEO Martina Molsbergen, is experienced in securing licensing agreements and joint ventures in the pharmaceutical industry.
- The agreement includes a management fee and an outcome-based success component aligning the interests of both parties.
- C14 will manage existing discussions and expand outreach to potential pharmaceutical partners.
- Dr. Ron Shnier, Vectus Non-Executive Chairman, expressed contentment in partnering with C14.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Allegra Medical Technologies Limited (AMT) ORDINARY FULLY PAID |
Health Care |
- |
Change of Director's Interest Notice - SM
|
30 Aug 2024 10:31AM |
$0.029 |
$0.029 |
fallen by
0%
|
|
| Sayona Mining Limited (SYA) ORDINARY FULLY PAID |
Materials |
$185 |
Annual Report to Shareholders
|
30 Aug 2024 10:29AM |
$0.027 |
$0.016 |
fallen by
39.62%
|
|
| Lark Distilling Co. Ltd (LRK) ORDINARY FULLY PAID |
Consumer Staple |
$85 |
Chair's EGM Address & CEO Presentation
|
30 Aug 2024 10:27AM |
$0.940 |
$0.805 |
fallen by
14.36%
|
|
| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$7,446 |
Application for quotation of securities - EBO
|
30 Aug 2024 10:27AM |
$32.320 |
$36.640 |
risen by
13.37%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$358 |
Full-Year Results Presentation
|
30 Aug 2024 10:25AM |
$0.178 |
$0.270 |
risen by
52.11%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
